Novavax

While demand for COVID-19 shots in the U.S. has dropped off dramatically, the need for more vaccines around the world remains critical.
The Maryland-based company said Thursday that it was “very encouraged by the data” from its phase 3 clinical trial in the U.K.
Though promising, the results raise concerns about vaccines’ power as the coronavirus continues to mutate.
Public health experts say more options in addition to the two vaccines now being dispensed are critical to amassing enough shots for the country.